SCHEMBL14224528

SCHEMBL14224528

Cn1cc(NC(=O)c2cc3ccccc3cn2)cc1C(=O)Nc1cc(-c2nc3cc(NC(=O)CCN4CCOCC4)ccc3[nH]2)n(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
TERT O14746 1/20 0.42
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALOX15 P16050 1/20 0.40
PAK1 Q13153 1/20 0.40
NPY5R Q15761 1/20 0.40
WNT1 P04628 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
BCHE P06276 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14224673 0.89 PDGFRB (0.45) KDM4EHPGDHSD17B10ALDH1A1RAB9A
SCHEMBL14224534 0.83 MAPT (0.40) KDM4EHPGDALDH1A1RAB9ANPC1
SCHEMBL14426980 0.82 MAPT (0.39) RAB9AABCB1ABCG2EGFR
SCHEMBL14427363 0.82 MAPT (0.39) RAB9ANPC1POLBHTTLMNA
SCHEMBL14224537 0.81 MAPT (0.39) RAB9ANPC1POLBHTTLMNA
SCHEMBL14426984 0.77 MAPT (0.41) RAB9ANPC1TP53POLBHTT
SCHEMBL14224524 0.72 MAPT (0.37) KDM4ERAB9ANPC1TP53POLB
SCHEMBL27922099 0.70 KDM4E (0.59) KDM4EHPGDHSD17B10ALDH1A1RAB9A
SCHEMBL14224525 0.69 MAPT (0.35) POLBEGFR
SCHEMBL13520198 0.68 EGFR (0.49) KDM4EALDH1A1RAB9ANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS GENESOFT PHARMACEUTICALS, INC. (US) 2008-04-17 US disclosed
US-7265129-B2 Anti-infective biaryl compounds GENESOFT PHARMACEUTICALS, INC. (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS QTRT1, Q6ZSR9, QTRT2 KDM4E 3096/4885HPGD 4306/4885HSD17B10 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.